CGM Category Update: Clinical Outcomes, New Technologies, Therapeutic Dosing and Patient Access

Statement of Need:

Self-monitoring of blood glucose (SMBG) is a core component of a diabetic patient’s management but only provides a measurement of blood glucose levels at a specific point in time, often missing trends, hyperglycemic or hypoglycemic excursions. HbA1c is even more limited and reports an average reading over 90 days; therefore incapable of alerting the patient of fluctuations in blood glucose at any point in time.

Selection of an appropriate Continuous Glucose Monitoring (CGM) device is important because improvements in accuracy and reliability are ongoing. RT-CGM is one cornerstone of optimal glycemic control. Each varies; relying on different sensing technology and requiring the traditional finger-stick for confirmation of alerts. The Mean Absolute Relative Difference (MARD) between sensor readings and reference glucose levels can vary by as much as 20% with worrisome discrepancies in the hypoglycemic range. But new generation devices have significantly improved MARD measurements. These devices have shorter lag times and improvements in accuracy. Many physicians are lacking the appropriate level of knowledge to employ CGM as part of their practices.

Significant improvements in accuracy of CGM sensors and device algorithms have made CGM-based treatment decisions a current reality. This program will evaluate the clinical application of CGM in diabetes management decisions and the importance of various aspects of CGM to guide optimal treatment, regardless of insulin mode of administration.


Please Note: this course is housed on CogniMed Education. Upon selecting 'Take Course,' you will be redirected to Register and to complete the activity.

Target Audience

Diabetologists, Endocrinologists, Primary Care Physicians, Nurse Practitioners, Certified Diabetes Educators, Pharmacists, and other Health Care Professionals interested in the management of diabetes attending the respective 2018 AACE Annual Meeting.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  1. Recognize the role of CGM and its clinical benefit for patients using multiple daily injections.
  2. Employ real-time insulin dosing methods using CGM information to make more informed diabetes management decisions.
  3. Identify therapeutic CGM as a unique category, defined by Medicare, as CGM that does not require fingersticks to confirm diabetes management decisions; review the clinical study that proves CGM dosing is safe and efficacious.
Additional information
AttachmentSize
Program Disclosures568.79 KB
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Course summary
Available credit: 
  • 1.75 AMA
  • 1.75 Attendance
Course opens: 
10/18/2018
Course expires: 
10/18/2019
Cost:
$0.00

Welcome and Introduction
Kathleen Wyne, MD, PhD, FACE, FNLA
CGM Category Update
George Grunberger, MD, FACP, FACE
Novel CGM in Clinical Practice
Kathleen Wyne, MD, PhD, FACE, FNLA
Patient Access to CGM
Felice Caldarella, MD, FACP, CDE, FACE
Questions and Answers (moderated by Kathleen Wyne, MD, PhD, FACE, FNLA)
All Faculty

Kathleen Wyne, MD, PhD, FACE, FNLA

Associate Professor of Clinical Medicine
Division of Endocrinology, Diabetes and Metabolism, College of Medicine 
The Ohio State University Wexner Medical Center
Columbus, OH

Felice Caldarella, MD, FACP, CDE, FACE

Secretary
American Association of
Clinical Endocrinologists
Endocrinologist
Center for Endocrine Health
Clinton, New Jersey

George Grunberger, MD, FACP, FACE

Clinical Professor of Internal
Medicine and Genetics
Wayne State University School of Medicine
Professor of Medicine
Oakland University
William Beaumont School of Medicine
Grunberger Diabetes Institute
Bloomfield Hills, Michigan

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.75 AMA
  • 1.75 Attendance

Accreditation Period

Course opens: 
10/18/2018
Course expires: 
10/18/2019

Price

Cost:
$0.00
Please login or register to take this course.